E. Alton

发表

Mannose-binding lectin is present in the infected airway: a possible pulmonary defence mechanism

D. Geddes, N. Klein, M. Turner, 2008, Thorax.

P95 Assessment of F/HN-pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy

J. Davies, M. Hasegawa, D. Gill, 2012, Thorax.

Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium

C. Kitson, B. Wainwright, S. Ferrari, 2001, Gene Therapy.

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung

D. Porteous, D. Shaw, R. Scheule, 2011, Gene Therapy.

The pathogenic consequences of a single mutated CFTR gene

D. Geddes, U. Griesenbach, E. Alton, 1999, Thorax.

Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury.

M. Goddard, D. Geddes, M. Stern, 2005, American journal of physiology. Lung cellular and molecular physiology.

S127 Gene therapy for alpha-1-antitrypsin deficiency using a pseudotyped lentivirus vector

M. Hasegawa, I. Pringle, D. Gill, 2015 .

Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy

A. Inness, J. Davies, M. Hasegawa, 2014 .

Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis

D. Porteous, S. Cunningham, P. Gustafsson, 2007, Thorax.

P79 Comparison of CF and Non CF LCI results using the Exhalyzer D and InnocorTM devices

J. Davies, E. Alton, C. Saunders, 2015 .

Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition.

D. Geddes, T. Pitt, A. Bush, 1999, The European respiratory journal.

Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers

D. Geddes, E. Alton, D. Meeker, 1998, Gene Therapy.

Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers

D. Geddes, E. Alton, D. Meeker, 1997, Gene Therapy.

Progress and prospects: gene therapy clinical trials (part 1) (vol 14, pg 1439, 2007)

R. Ali, J. Bainbridge, T. Flotte, 2007 .

Computed tomography and cystic fibrosis: promises and problems

D. Hansell, D. Geddes, A. Wells, 2007, Thorax.

Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial

S. Durham, D. Geddes, Seng H. Cheng, 1999, The Lancet.

Measure and interpretation of CF gene therapy trial results.

D. Porteous, D. Gill, J. Innes, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

UKCF gene therapy consortium tracking study: Lung clearance index improves with treatment of an infective exacerbation

D. Porteous, D. Geddes, R. Gray, 2007 .

WS17.5 Nasal potential difference measurement increases the diagnostic yield in patients with equivocal first-line cystic fibrosis investigations: the experience of a large national CFTR diagnostic service

J. Davies, N. Simmonds, R. Pabary, 2018, Journal of Cystic Fibrosis.

Cytoplasmic deposition of NFκB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation

E. Alton, R. Cassady, D. Geddes, 2002, Gene Therapy.

Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium.

D. Geddes, E. Alton, E. Alton, 1994, The European respiratory journal.

Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence.

D. Geddes, M. Evans, W. Colledge, 2001, The European respiratory journal.

A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

D. Porteous, B. Wainwright, J. Dorin, 1996, Gene therapy.

T4 Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis

R. Scheule, S. Hyde, D. Gill, 2011, Thorax.

Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP.

D. Porteous, G. Mclachlan, E. Alton, 1996, Gene therapy.